{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"97"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"37"}]}],"title":"No"}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"134"}],"units":"Participants"}],"description":"Measurement of anti-adenoviral antibody levels at each dosing period, withdrawal, and at 12 months were done. A patient was considered to have a positive immunogenic response in anti-adenoviral antibodies if a post-baseline titration demonstrated a greater than a 2-fold dilution increase from baseline.\n\nThe table represent data at any time during the 12 months period, which means that the patients were included in the Yes group if they at any measurement during the trial had a 2-fold dilution increase from baseline.","groups":[{"description":"Patients with Carcinoma in situ (CIS) with or without concomitant high-grade Ta or T1 papillary disease","id":"OG000","title":"Carcinoma in Situ"},{"description":"Patients with high-grade Ta or T1 papillary disease (without concomitant CIS)","id":"OG001","title":"Papillary Disease"},{"description":"All patients","id":"OG002","title":"Total"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients with Positive Immunogenic Response in Anti-Adenoviral Antibodies at Post-Baseline based on patients who had achieved High-Grade Recurrence Free Survival at 12 months","reportingStatus":"POSTED","timeFrame":"12 Months","title":"Anti-adenoviral Antibody Levels for Correlation to Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}